Data Readout

LEO Pharma's tralokinumab clears PK bar in atopic dermatitis children aged 6 to 11

TRAPEDS-1 met its pharmacokinetic objective in 28 children, but the enrollment target was cut nearly in half during the trial and no efficacy data have been released.

By AppliedXLJuly 9, 2026Trial NCT05388760

Executive Summary

LEO Pharma's pediatric trial of tralokinumab met its pharmacokinetic objective, with exposure and safety findings that track the drug's established profile rather than breaking new ground.
The study was designed to characterize dosing and tolerability in a younger age group for an already-approved biologic, not to prove efficacy, so the readout supports dose selection rather than a treatment claim.
The trial's enrollment target was cut substantially partway through, a change large enough to register as elevated under the sponsor's own risk framework, even though the study still delivered on its stated objective.
The efficacy question for this age group now sits with a separate, ongoing Phase 3 trial, making that program the one to watch for a clinical benefit signal.

The disclosure

LEO Pharma announced on July 9, 2026 that the TRAPEDS-1 trial (NCT05388760) met its primary objective of characterizing the pharmacokinetics of tralokinumab, an IL-13-targeting monoclonal antibody, in children aged 6 to 11 years with moderate-to-severe atopic dermatitis. The company said the pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Sophie Lamle, LEO Pharma's EVP of Development, said completing TRAPEDS-1 "marks an important milestone in our pediatric clinical development program for tralokinumab". LEO

Probability of Success

Endpoint Met86%

Completes79%

Clinical Significance21%

Regulatory89%

How it was done

TRAPEDS-1 was a Phase 2, randomized, assessor-blinded, parallel-group, multicenter monotherapy trial run across 11 sites in five countries: Spain, the United Kingdom, Czechia, the Netherlands, and France. Patients were randomized to one of two tralokinumab dose regimens for an initial 16-week treatment period, with primary endpoints of AUC, Cmax, Ctrough, and Tmax. All patients then entered an open-label extension and continued tralokinumab for up to 172 weeks total, followed by a 16-week off-treatment safety follow-up. The trial enrolled 28 patients and completed on April 29, 2026, with a primary completion date of October 20, 2023. NCT05388760+1

The safety read

Across the initial, open-label, and long-term extension periods, tralokinumab was generally well tolerated, and the safety data observed was consistent with the drug's known safety profile, LEO Pharma said. Most adverse events were non-serious and mild to moderate in severity. Lead investigator Michael Cork, professor of dermatology and co-director of Sheffield Dermatology Research at the University of Sheffield, said the results support the drug's use "given the long duration of exposure in a pediatric population with high disease burden," adding that clinicians treating children with chronic inflammatory disease rely on data that "provide consistency and reduce uncertainty". LEO

The enrollment story

The trial's registered enrollment target dropped from 53 to 24 patients in a May 2024 registry update, before the trial closed with 28 patients enrolled, a 54.7% reduction from the original target. That decline clears the threshold the trial's own operational-risk model uses to flag an elevated enrollment change, and the primary completion date also moved twice, first pulled from August 2024 to September 2023, then reset to October 2023. The trial nonetheless progressed to a clean Completed status in May 2026, and the sponsor's press release characterizes the pharmacokinetic objective as met. NCT05388760+1

Where tralokinumab stands

Tralokinumab is already approved in adults as ADBRY, per FDA records, and LEO Pharma's press release stated explicitly that its safety and efficacy in patients aged 6 to 11 has not been evaluated by regulatory agencies. Because the drug's adult and adolescent efficacy and safety profile is already established, this pediatric PK study is a bridging exercise: the bar was reproducing tralokinumab's known exposure and tolerability pattern in a younger age band, not proving a new clinical effect. A separate, ongoing Phase 3 trial, TRAPEDS-2, is evaluating tralokinumab's efficacy and safety in children and infants with moderate-to-severe atopic dermatitis, and that trial carries the pediatric efficacy question forward. LEO

The competitive field

IL-13-targeted biologics have an established track record in atopic dermatitis: of 13 completed Phase 2 trials for IL-13 in this indication, none have been terminated. The pediatric and adolescent atopic dermatitis field around this target and modality includes Eli Lilly's lebrikizumab, also an IL-13 antibody, running two Phase 3 trials in overlapping pediatric age ranges, and Regeneron's dupilumab, an IL-4/IL-13 pathway antibody already studied in adolescents with atopic dermatitis. Sixteen active trials are studying IL-13 in atopic dermatitis broadly, indicating a field that is active but built on a validated mechanism rather than an emerging or unproven one.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.